Æterna Zentaris (AEZS) and Partner Keryx Biopharma (KERX) Report on Phase 2 of Perifosine Waldenstrom's Macroglobulinemia Treatment
Tweet Send to a Friend
Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
